{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Functioning",
      "Major depression disorder",
      "Residual symptoms"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "25149132",
  "DateCompleted": {
    "Year": "2015",
    "Month": "10",
    "Day": "14"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "12",
    "Day": "02"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2014",
        "Month": "08",
        "Day": "01"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.psychres.2014.07.042",
      "S0165-1781(14)00621-0"
    ],
    "Journal": {
      "ISSN": "1872-7123",
      "JournalIssue": {
        "Volume": "220",
        "Issue": "1-2",
        "PubDate": {
          "Year": "2014",
          "Month": "Dec",
          "Day": "15"
        }
      },
      "Title": "Psychiatry research",
      "ISOAbbreviation": "Psychiatry Res"
    },
    "ArticleTitle": "Individual residual symptoms and functional impairment in patients with depression.",
    "Pagination": {
      "StartPage": "258",
      "EndPage": "262",
      "MedlinePgn": "258-62"
    },
    "Abstract": {
      "AbstractText": [
        "The aim of treatment of depression is remission of symptoms and functioning. Although there is a relationship between remission of symptoms and remission of functioning, it is not known how individual residual symptoms are related to functioning. Here we report a post-hoc analysis of two studies which treated depressed patients with duloxetine in an open fashion for 10-12 weeks. We evaluated the association of individual residual symptoms and functional impairment in patients who remitted or partially remitted after acute treatment. Logistic regression was used to investigate residual symptoms associated with functional impairment at endpoint. Our results suggest that in partial remitters, the only residual symptom associated with a reduction in the risk of having impaired function was the resolution of painful physical symptoms (PPS). In patients who remitted, the presence of residual core mood symptoms (CMS), particularly in patients without any anxiety, predicted impaired functioning. The resolution of PPS in the presence of residual CMS was associated with less risk of impaired functioning. Our results contribute to understand better the role of specific residual symptoms on functional impairment. To achieve normal functioning, intervention on specific residual symptoms is recommended."
      ],
      "CopyrightInformation": "Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Clinical Research Lilly, S.A. Avenida de la Industria 30, 28108 Alcobendas, Spain; Autonomous University of Barcelona, Spain. Electronic address: romera_irene@lilly.com."
          }
        ],
        "LastName": "Romera",
        "ForeName": "Irene",
        "Initials": "I"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Psychiatry, Hospital Santa Creu i Sant Pau, Autonomous University of Barcelona/CIBERSAM, Barcelona, Spain."
          }
        ],
        "LastName": "P\u00e9rez",
        "ForeName": "V\u00edctor",
        "Initials": "V"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Eli Lilly UK, Windlesham, UK."
          }
        ],
        "LastName": "Quail",
        "ForeName": "Deborah",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Eli Lilly, Global Statistical Sciences, Bad Homburg, Germany."
          }
        ],
        "LastName": "Berggren",
        "ForeName": "Lovisa",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Eli Lilly UK, Basingstoke, UK."
          }
        ],
        "LastName": "Lenox-Smith",
        "ForeName": "Alan",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universidad San Pablo CEU, Madrid, Spain."
          }
        ],
        "LastName": "Gilaberte",
        "ForeName": "Inmaculada",
        "Initials": "I"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Ireland",
    "MedlineTA": "Psychiatry Res",
    "NlmUniqueID": "7911385",
    "ISSNLinking": "0165-1781"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antidepressive Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Thiophenes"
    },
    {
      "RegistryNumber": "9044SC542W",
      "NameOfSubstance": "Duloxetine Hydrochloride"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antidepressive Agents"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Anxiety"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Depressive Disorder, Major"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Duloxetine Hydrochloride"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Pain"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Sleep Wake Disorders"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Thiophenes"
    }
  ]
}